Feb 24 (Reuters) - Hims & Hers HIMS.N said the U.S. FDA's decision that the shortage of Novo Nordisk's NOVOb.CO weight-loss and diabetes drugs had been resolved could constrain the telehealth firm's ability to continue providing access to compounded versions of the drugs on its platform once current inventory has been sold.
(Reporting by Sneha S K in Bengaluru)
((Sneha.SK@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.